Search research articles
Contact Us
Filters
Showing results (181-190 of 206) with videos related to
Page
of 21
Sort By:
Cancer Medicine
|
July 7, 2022
Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study
Angelina K C Fink, Amanda C DeRenzis, Shivanshu Awasthi, et al.
The Lancet. Respiratory Medicine
|
July 18, 2024
Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation
Hernan P Fainberg, Yuben Moodley, Isaac Triguero, et al.
Clinical Genitourinary Cancer
|
October 1, 2024
A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder
Casey Liveringhouse, Austin J Sim, Jingsong Zhang, et al.
European Urology Focus
|
February 8, 2025
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies
Drupad Annapureddy, Jacob I Taylor, Ashish M Kamat, et al.
BJU International
|
August 26, 2024
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer
Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, et al.
European Urology Oncology
|
October 11, 2025
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group
Roger Li, Patrick J Hensley, Marko Babjuk, et al.
Immunity
|
November 1, 2023
Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers
Subir Biswas, Gunjan Mandal, Carmen M Anadon, et al.
European Urology Oncology
|
December 18, 2024
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer
Jacob Taylor, Ashish M Kamat, Drupad Annapureddy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
European Urology
|
June 13, 2025
Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes
Sam S Chang, Bryn Launer, Vikram Narayan, et al.
Page
of 21
Search research articles
Search
Showing results (181-190 of 206) with videos related to
Sort By:
Page
of 21
Cancer Medicine
|
July 7, 2022
Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study
Angelina K C Fink, Amanda C DeRenzis, Shivanshu Awasthi, et al.
The Lancet. Respiratory Medicine
|
July 18, 2024
Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation
Hernan P Fainberg, Yuben Moodley, Isaac Triguero, et al.
Clinical Genitourinary Cancer
|
October 1, 2024
A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder
Casey Liveringhouse, Austin J Sim, Jingsong Zhang, et al.
European Urology Focus
|
February 8, 2025
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies
Drupad Annapureddy, Jacob I Taylor, Ashish M Kamat, et al.
BJU International
|
August 26, 2024
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer
Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, et al.
European Urology Oncology
|
October 11, 2025
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group
Roger Li, Patrick J Hensley, Marko Babjuk, et al.
Immunity
|
November 1, 2023
Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers
Subir Biswas, Gunjan Mandal, Carmen M Anadon, et al.
European Urology Oncology
|
December 18, 2024
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer
Jacob Taylor, Ashish M Kamat, Drupad Annapureddy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
European Urology
|
June 13, 2025
Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes
Sam S Chang, Bryn Launer, Vikram Narayan, et al.
Page
of 21